Methods of decreasing intestinal motility
2 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to a method of decreasing intestinal motility in a subject in need of treatment. The method comprises administering to the subject a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of decreasing intestinal motility in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. In certain embodiments, the subject is a subject with a functional bowel disorder, such as IBS, functional abdominal bloating, or functional diarrhea.
-
Citations
107 Claims
-
1-62. -62. (canceled)
- 63. A method of decreasing intestinal motility in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound of formula I:
-
77. A method of decreasing intestinal motility in a subject in need thereof comprising administering to said subject:
-
a) a first amount of a 5-HT3 receptor antagonist; and
b) a second amount of a noradrenaline reuptake inhibitor wherein the first and second amounts together comprise a therapeutically effective amount. - View Dependent Claims (78, 79, 80, 81, 82, 83, 84, 85, 86, 87)
-
-
88. A method of decreasing intestinal motility in a subject in need thereof comprising administering to said subject:
-
a) a therapeutically effective amount of a 5-HT3 receptor antagonist; and
b) a therapeutically effective amount of a noradrenaline reuptake inhibitor. - View Dependent Claims (89, 90, 91, 92, 93, 94, 95, 96, 97, 98)
-
- 99. A method of decreasing intestinal motility in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a noradrenaline reuptake inhibitor, wherein the noradrenaline reuptake inhibitor characterized by the substantial absence of anticholinergic effects.
Specification